ArticleJournal of hepatocellular carcinoma2025
Impact of Middle Hepatic Vein Resection During Hemihepatectomy on Surgical Outcomes and Long-Term Prognosis in Hepatocellular Carcinoma: A Retrospective Study.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Diagnostic accuracy of circulating long noncoding RNAs in hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Comparison of proton vs. photon radiotherapy for liver cancer: a meta-analysis.BMC gastroenterology · 2026Pooled it
- Circular RNAs in hepatocellular carcinoma: a systematic qualitative review of regulatory mechanisms, therapeutic resistance, and clinical translation.BMC gastroenterology · 2026Pooled it
- Diagnostic performance of artificial intelligence models in hepatocellular carcinoma: a systematic review and diagnostic meta-analysis.BMC gastroenterology · 2026Pooled it
- Preoperative gamma-glutamyltransferase-to-lymphocyte ratio and prognosis after curative hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs.BMC gastroenterology · 2026Pooled it
- Role of extracellular matrix in liver fibrosis regression and regeneration (Review).International journal of molecular medicine · 2026Review
- Intratumoral but not circulating estradiol predicts postoperative survival in men with hepatocellular carcinoma.Discover oncology · 2026Article
- Integrated multi-omic and functional profiling reveals a ZDHHC16-associated palmitoylation-proteostasis state in hepatocellular carcinoma.Discover oncology · 2026Article
- Article
- Worse Prognosis of Patients With Hepatocellular Carcinoma and Portal Vein Invasion Underestimated by Imaging.World journal of surgery · 2026Article
- Development and validation of a nomogram to predict recurrence after hepatectomy in overweight patients with hepatocellular carcinoma: a retrospective cohort study.BMC gastroenterology · 2026Article
- Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy.BMC gastroenterology · 2026Article
- M²B-Net: a lightweight multi-scale multi-attention boundary-aware network for liver tumor segmentation from CT images.Scientific reports · 2026Article
- POTEF upregulation drives hepatocellular carcinoma progression via oncogenic signaling and immune modulation.Scientific reports · 2026Article
- Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study.Scientific reports · 2026Article
- Evaluation of the predictive accuracy of nine staging systems in patients with hepatocellular carcinoma: a multicenter, retrospective study in China.Scientific reports · 2026Article
- TLCD1 correlates with malignant progression of hepatocellular carcinoma and activation of the ERK signaling cascade.Scientific reports · 2026Article
- Multi-omics integration model of exosome metabolomics and PD-1/PD-L1 expression for early prediction of immunotherapy efficacy in advanced liver cancer.Scientific reports · 2026Article
- Predictors and outcomes of hepatic decompensation following transarterial locoregional therapy in hepatocellular carcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the impact of middle hepatic vein (MHV) resection during hemihepatectomy on short-term surgical outcomes and long-term prognosis in patients with hepatocellular carcinoma (HCC). Patients and Methods: Patients with HCC at Barcelona Clinic Liver Cancer (BCLC) stages 0-B who underwent hemihepatectomy between January 2016 and December 2022 were retrospectively screened. They were categorized into the MHV-preserved and MHV-resected groups. Intraoperative parameters, postoperative complications, liver function, overall survival (OS), and recurrence-free survival (RFS) were compared. Cox regression analyses were used to identified independent risk factors for OS and RFS. Results: A total of 137 patients were included, of whom 107 (78.1%) had MHV preserved and 30 (21.9%) had MHV resected. Compared with MHV preservation, MHV resection was associated with a longer operative time (329.9 ± 108.0 vs 291.4 ± 88.9 min, Conclusion: MHV resection during hemihepatectomy increases operative time, blood loss, and postoperative liver enzyme levels, but does not significantly impact long-term survival in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.